Snippet of encouraging data keeps Oxford and AstraZeneca on COVID-19 vaccine radar

19 November 2020

University of Oxford and AstraZeneca have been beaten by companies on the other side of the Atlantic in their quest to show efficacy of their COVID-19 vaccine in a late-stage trial.

However, they have managed to grab back some of the focus through data published on Thursday by The Lancet, showing that the ChAdOx1 nCoV-19 vaccine triggers a robust immune response in healthy adults aged 56 to 69 years, and those over 70 years of age.

"Older adults are a priority group for COVID-19 vaccination"Reporting on data from a Phase II trial of the ChAdOx1 nCov-2019 vaccine, the authors write that volunteers in the trial demonstrate similar neutralizing antibody titres, and T-cell responses across adult age ranges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK